Category: Pharmaceutical Industry
-
Boehringer wins nintedanib PI against Zentiva as UPC CoA reverses Lisbon LD on when infringement is imminent, clarifies how to argue national law
Context: Three months ago, the Unified Patent Court’s (UPC) Lisbon Local Division (LD) denied an application for provisional measures (which in some other jurisdictions would be called a motion for a preliminary injunction (PI)) by Boehringer Ingelheim against Zentiva, holding that an infringement did not appear imminent (item 2 of our May 10, 2025 UPC…
-
BREAKING: GSK cashes in on license deal as CureVac settles U.S. patent dispute with acquirer BioNTech and Pfizer for $790M+
Pfizer and BioNTech have settled their three-year COVID vaccine-related patent infringement dispute with CureVac in the U.S., granting the latter and its licensing partner GSK $370 million each.
-
An interview with Bayer’s outgoing head of IP Dr. Jörg Thomaier, new head Dorian Immler
Following three decades at Bayer, Dr. Jörg Thomaier is retiring as head of IP, super confident that his replacement Dorian Immler will have the energy and drive to make the changes that the department needs to keep prospering.
-
Novo Nordisk suffers loss over negative claim limitation in ongoing patent dispute over diabetes drug Wegovy
The United States District Court for the District of Delaware has ruled that Viatris has not induced the infringement of one of five asserted patents in litigation initiated by Novo Nordisk.
-
U.S. appeals court revokes Novartis short-term injunction in Entresto patent dispute against MSN
Decision allows MSN to launch its generic version of Entresto into the market, and opens the door for others to follow.
-
U.S. appeals court grants Novartis short-term injunction in Entresto patent dispute with MSN: non-skilled-artisan testimony is key issue
The Federal Circuit has granted Novartis a few more days of Entresto exclusivity through a short-term injunction against MSN.
-
EWCA heard Pfizer, BioNTech appeal against Moderna’s COVID vaccine patent win
After losing a major ruling in the High Court of Justice in London last year, Pfizer and BioNTech asked the England & Wales Court of Appeal to overturn a decision finding a key Moderna COVID patent was valid and infringed.
-
Novartis denied injunctive relief against MSN in chronic heart failure patent fight: next stop emergency motion for injunction pending appeal?
Novartis cannot block rival MSN Pharmaceuticals from launching a generic version of its chronic heart failure treatment Entresto before its patent expires in November 2026, the District of Delaware has held.
-
Brain medtech firm Ceribell files ITC complaint against rival Natus Medical over seizure-detection tech patents
The Nasdaq-listed company has also sued its competitor in the District of Delaware, asserting six patents related to electroencephalography technologies used in seizure-detection devices.
-
UPC’s Court of Appeal: rehearings will rarely (if ever) happen, and UPC representatives MUST know EPO’s appellate case law
Context: Things have not gone well so far for Alexion Pharmaceuticals’ patent infringement actions against Amgen and Samsung Bioepis. Six months ago, the Unified Patent Court’s (UPC) Court of Appeal (CoA) affirmed (December 23, 2024 ip fray article) the Hamburg Local Division’s (LD) orders denying preliminary injunctions (PIs; officially called “provisional measures” in the UPC).…